DUALITYBIO Inc. (HKEX: 09606; “DualityBio” or the “Company”) today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates (“ADCs”) built on the Company’s proprietary DualityBio Unique Payload Antibody Conjugate (“DUPAC”) platform.Read More
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio’s DUPAC Novel-Payload Platform
By PR Newswire
